Evidence-based summary of the management for immune checkpoint inhibitor-rela-ted cutaneous toxicity
Objective To evaluate and summarize the evidence regarding the management of immune checkpoint inhibitor-related cu-taneous toxicity,and to provide a basis for healthcare professionals to manage cancer patients developing immune checkpoint inhib-itor-related cutaneous toxicity.Methods A systematic search was conducted in relevant domestic and international websites and da-tabases.Guidelines,expert consensus reports,evidence summary reports,systematic reviews,and other evidence on the manage-ment of immune checkpoint inhibitor-related cutaneous toxicity in cancer patients were included.The search timeframe was from database inception to April 30,2024.Two researchers with expertise in evidence-based nursing independently assessed the quality and level of evidence of the literature.Results A total of 19 articles were included,comprising 7 guidelines,10 expert consensus statement reports,1 systematic review,and 1 clinical decision-making report.Nineteen pieces of best-evidence were formulated from five aspects:prevention,assessment,examination,treatment and care,and monitoring.Conclusion Effective management of immune checkpoint inhibitor-related cutaneous toxicity can alleviate cutaneous symptoms and improve patients'quality of life.Healthcare professionals should consider patients'preferences and tailor personalized guidance based on clinical circumstances for patients with immune checkpoint inhibitor-related cutaneous toxicity in cancer treatment.
tumorimmunotherapyimmune checkpoint inhibitorcutaneous toxicityadverse drug reactionsevidence-based nursingskin care
万方数据
维普
